^
    Chr t(15;17)
    Acute Promyelocytic Leukemia
    arsenic trioxide
    Sensitive: A1 - Approval
    PML-RARA fusion
    Acute Promyelocytic Leukemia
    arsenic trioxide
    Sensitive: A1 - Approval
    No biomarker
    Acute Promyelocytic Leukemia
    gemtuzumab ozogamicin
    Sensitive: A2 - Guideline
    No biomarker
    Acute Promyelocytic Leukemia
    cytarabine + daunorubicin
    Sensitive: A2 - Guideline
    PML-RARA fusion
    Acute Promyelocytic Leukemia
    tretinoin + arsenic trioxide
    Sensitive: C3 – Early Trials
    STAT5b-RARA fusion
    Acute Promyelocytic Leukemia
    DCAG
    Sensitive: C4 – Case Studies
    PML-RARA fusion
    Acute Promyelocytic Leukemia
    cytarabine + idarubicin hydrochloride + tretinoin
    Sensitive: C4 – Case Studies
    FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression
    Acute Promyelocytic Leukemia
    cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea
    Sensitive: C4 – Case Studies
    PML-RARA T285I
    Acute Promyelocytic Leukemia
    venetoclax
    Sensitive: C4 – Case Studies
    ZBTB16-RARA fusion
    Acute Promyelocytic Leukemia
    chidamide
    Sensitive: D – Preclinical
    STAT5b-RARA fusion
    Acute Promyelocytic Leukemia
    chidamide
    Sensitive: D – Preclinical
    NPM-RARA fusion
    Acute Promyelocytic Leukemia
    chidamide
    Sensitive: D – Preclinical